KANE
BIOTECH

WITH COACTIV+™ TECHNOLOGY

revyve®
ANTIMICROBIAL WOUND GEL

XSONX™
HEAL WOUNDS BETTER

Triple Action Innovation

Changing The Paradigm of Wound Care

revyve™ Antimicrobial Wound Gel is changing the paradigm of wound care as the only product on the market that combines the unique triple-action formulation of a powerful antimicrobial, our patented coactiv+™ antibiofilm technology and a high-concentration surfactant, with our dynamic smartFILL™ gelling system, for optimal wound healing.

1. Kane's patented coactiv+™ antibiofilm technology
Specifically formulated to disrupt biofilm structures (1, 2), inhibit excessive protease levels(3), and maintain mildly acidic wound pH, ideal for healing. (4)
2. PHMB Antimicrobial
Provides lasting antimicrobial activity for a minimum of 7 days (5, 6), supports healing without inhibiting epithelialization (7-9), is biocompatible and has a high therapeutic index (8, 9) with no antimicrobial resistance development. (9)
3. Highly-Concentrated Surfactant Gel
Aids autolytic debridement, naturally removing dead tissue (10, 11), maintains an optimal moist wound environment without causing maceration (12), and form-fits and strongly adheres to wounds. (5, 6, 13)

Innovative Vibrational Debridement Technology:

XSONX® Wound Hygiene System is a battery powered wound therapy system with innovative Vibrational Debridement Technology (VDT) to powerfully clean and debride wounds. XSONX® helps speed up the wound healing process by removing exudates, devitalized tissue, bacterial biofilm, slough, fibrin, and excised or fragmented tissue and offers:

- less pain and anxiety for the patient
- ease of use for practitioners
- reduced procedural time and cost savings
- precise and uniform debridement
- superior wound bed prep prior to tissue grafting
- significant reduction in bioburden especially when used in combination with revyve™ Antimicrobial Wound Gel.

Novel Debridement and Wound Care Approach for Venous Leg Ulcers Non-Responsive to Standard Therapy

Rohan Pointer, MD; Iris Noland, MD; Miloslav Sailer, PhD

Kane Biotech Inc,
Winnipeg, Manitoba, Canada
Contact: msailer@kanebiotech.com

Case History

A 72 year-old female known for COPD and a fracture of her left ankle early in life requiring multiple surgeries, presented with a venous ulcer of the medial malleolus of her left ankle.

Clinical Situation

This woman was very active and walked more than 5km daily. Despite compressive bandages, the ulcer had not healed over the last 2 years. The patient was quite discouraged.

Actions Taken

A new treatment was undertaken in January 2025 consisting of weekly mechanical debridement with XSONX® and application of revyve™ Antimicrobial Wound Gel.

Jan. 6	11.0x2.7cm	**22.2cm2**
Jan 23	9.0x3.0cm	**20.5cm2**
Feb 14	9.0x2.8cm	**17.7cm2**
March 3	10.4x2.5	**15.8cm2**
March 14	6.8x2.0cm	**8.6cm2**
NB - Jan 6th to March 14th = -65.3% reduction in wound size		

Outcomes

Over the course of 8 weeks, there was a greater than 60% reduction in wound surface area. The treatment was well tolerated by the patient. She reported improved morale.


January 6, 2025


February 7, 2025


March 3, 2025

Implication for Practice

The combination of XSONX® with the revyve™ Antimicrobial Wound Gel shows the potential benefits in the management of chronic venous leg ulcers that have not responded to standard care.

References

(1). Finnegan S, Percival SL. EDTA: An Antimicrobial and Antibiofilm Agent for Use in Wound Care. Adv Wound Care (New Rochelle). 2015 Jul 1;4(7):415–21. (2). Gawande G, LoVetri K, Yakandawala N, Froelich G, Madhyastha S. Antimicrobial-antibiofilm compositions and methods of use thereof [Internet]. Winnipeg, MB; US9980497B2, 2018. Available from: https://patents.google.com/patent/US9980497B2 (3). Visvalingam J, Yakandawala N, Regmi S, Lee SP, Sailer M. A Chelation approach to biofilm and metalloprotease problem in chronic Wounds. In: he Symposium on Advanced Wound Care Spring. National Habor, BD, USA.; 2023. (4). Rodgers A, Watret L. The role of pH modulation in wound bed preparation. The Diabetic Foot. 2005;8(3):154–7. (5). Visvalingam J, Regmi S, Lee SP, Edwards M, Abdo R, Schultz G. A thermo-reversible hydrogel against chronic, burn and combat wound associated pathogens, and its application to colonized wounds. In: The Symposium on Advanced Wound Care Spring. Orlando, FL, USA; 2024. (6). Sailer M, Visvalingam J, Regmi S, Muzaleva A, Schultz G. A novel thermo-reversible antimicrobial hydrogel spray with effective antibiofilm properties to treat complex combat wounds. MHSRS, in Kissimmee FL, USA; 2024. (7). Hübner NO, Kramer A. Review on the Efficacy, Safety and Clinical Applications of Polihexanide, a Modern Wound Antiseptic. Skin Pharmacol Physiol. 2010;23(Suppl. 1):17–27. (8). Gray D, Barrett S, Battacharyya M, Butcher M, Enoch S, Fumerola S, et al. PHMB and its potential contribution to wound management. Wounds UK. 2010;6(2):40–6. (9). Rippon MG, Rogers AA, Ousey K. Polyhexamethylene biguanide and its antimicrobial role in wound healing: a narrative review. J Wound Care. 2023 Jan 2;32(1):5–20. (10). Percival SL, Chen R, Mayer D, Salisbury A. Mode of action of poloxamer-based surfactants in wound care and efficacy on biofilms. Int Wound J. 2018 Jun 5;15(5):749–55. (11). Percival SL, Mayer D, Kirsner RS, Schultz G, Weir D, Roy S, et al. Surfactants: Role in biofilm management and cellular behaviour. International Wound Journal. 2019 Jun;16(3):753–60. (12). Visvalingam J, Yakandawala N, Regmi S, Sharma P, Sailer M. Anti-biofilm and anti-metalloprotease activity of a novel wound gel. In: The Symposium on Advanced Wound Care Fall. Las Vegas, NV, USA; 2022. (13). Visvalingam J, Sailer M, Edwards M, Schultz G. A Novel Thermo-Reversible Antimicrobial Hydrogel Spray to Treat Complex Combat Wounds. In: MTEC Annual Meeting. Baltimore, MD, USA.; 2024.